Trial Profile
A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs BLI 1401 (Primary) ; Docetaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioLite Inc
- 16 Nov 2023 Planned End Date changed from 28 Feb 2025 to 28 Aug 2025.
- 16 Nov 2023 Planned primary completion date changed from 30 Oct 2024 to 30 Apr 2025.
- 16 Nov 2023 Planned initiation date changed from 1 Sep 2023 to 1 Mar 2024.